Podcasts about biopharma

  • 350PODCASTS
  • 855EPISODES
  • 28mAVG DURATION
  • 5WEEKLY NEW EPISODES
  • May 14, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about biopharma

Show all podcasts related to biopharma

Latest podcast episodes about biopharma

Pharma Intelligence Podcasts
China Biopharma Podcast - 14 May 2025 (Chinese language)

Pharma Intelligence Podcasts

Play Episode Listen Later May 14, 2025 25:01


在本期中国生物技术播客中,Dexter Yan回顾了他在4月的美国癌症研究协会年会(AACR)举办前和再鼎医药总裁及全球肿瘤研发负责人Rafael Amado的采访。Amado在采访中详细阐述再鼎在AACR展示的两个临床前项目,分别是PD-1/IL-12 双抗和靶向LRRC15的抗体偶联药物(ADC)。Dexter还采访到Arbele的创始人和CEO John Luk,请他介绍Arbele在钙粘蛋白17(CDH17)靶点研发上的最新进展和心得体会。最后Dexter回顾了4月维升药业和映恩生物在香港交易所首次上市的情况。 此外,Xu Hu分享了她最近撰写的有关中国企业研发肠促胰岛素类体重管理药物的综述。除此之外,Xu点评了中国药监局最近公布的有关药品试验数据保护的征求意见稿。

BioSpace
Trump's Drug Pricing Policy, Prasad's CBER Nod, Bayer's Layoffs and Galapagos' Next Chapter

BioSpace

Play Episode Listen Later May 14, 2025 31:06


President Donald Trump unveiled a sweeping drug pricing policy this week, seeking to lower drug prices in the U.S. by up to 80% through a reprisal of the Most Favored Nation rule he attempted to introduce in his first term. The rule would essentially link U.S. prices to those paid in other nations where medications are cheaper. Biopharma reaction was one of tentative relief, with BMO Capital Markets analysts suggesting the executive order had “more bark than bite.” Meanwhile, the Centers for Medicare and Medicaid Services announced that among the next 15 drugs to undergo IRA-prescripted price negotiations could be drugs payable through Medicare Part B, and not just Part D, where the first two rounds have applied.  Into all of this action steps Vinay Prasad, the outspoken oncologist and hematologist who was named last week as the next director of the FDA's Center for Biologics Evaluation and Research. While the S&P Biotech ETF fell by more than 5% upon the news, overall reaction was fairly measured, with cell and gene therapy executive Audrey Greenberg summing up Prasad's selection as “anything but a status quo appointment.”  Over in the weight loss and obesity space, Eli Lilly can't seem to lose. This weekend, Lilly announced full data from a head-to-head trial showing a “superior benefit-to-risk ratio” for its Zepbound over Novo Nordisk's Wegovy. And last week, the Indiana-based pharma won a court battle against compounders when a judge sided with the FDA, stating that tirzepatide—the active ingredient in both Zepbound and diabetes sister drug Mounjaro—was no longer in shortage. Add on a presidential shoutout during Trump's Monday press conference for its U.S. manufacturing investments, and it really was Lilly's week.  Flying less high are some 2,000 Bayer employees who lost their jobs in the first quarter of 2025 as part of the company's new operating model, which is intended to make Bayer “much more agile.” On a less direct flight is Galapagos, which reversed course on plans to spin out a portion of the company and find a new CEO. Instead, CEO Paul Stoffels will make a quicker exit and the Belgian biotech could sell off its cell therapy assets as it looks to build up a new pipeline in house, having abandoned the spinout idea altogether. Stay tuned.  Finally, in ClinicaSpace this week, we took a deep dive into the HIV treatment space, where companies like Gilead and Immunocore are targeting a cure, while the Trump administration slashes funding for HIV research.  

ACRO's Good Clinical Podcast
S3: E4 Kernels of Wisdom: What Matters Most in Clinical Trial Monitoring

ACRO's Good Clinical Podcast

Play Episode Listen Later May 13, 2025 41:54


What does clinical trial monitoring have in common with growing a field of corn? Amy Kroeplin (PPD™ clinical research business of Thermo Fisher Scientific), Shailesh Madel (ICON plc), and Nicole Stansbury (Premier Research) join the podcast to discuss the importance of risk-based quality management, centralized monitoring, and strategic SDV/SDR sampling strategies. They dive deeper into the unique roles of SDV and SDR, different methods of implementing SDV/SDR sampling strategies, and the industry imperative to increase centralized monitoring adoption.

Biotalk
Episode 27: Inside the Biopharma Market: 2025 Outlook & Emerging Trends

Biotalk

Play Episode Listen Later May 7, 2025 7:47


During Episode 27 of Biotalk, Geoff Meyerson, CEO of Locust Walk, steps back to examine the macro forces shaping the biopharma landscape. After holding a bearish outlook since 2021, Geoff explains why he's finally shifting his stance and what could signal a true turnaround for biotech. He unpacks the “big three” market headwinds—regulatory hurdles from the IRA, FTC deal scrutiny, and high interest rates—and outlines how recent shifts, including rate cuts, new FTC leadership, and potential IRA reform, could spark renewed momentum, especially in M&A and rare diseases. Geoff also highlights previously underappreciated risks like HHS cuts and aggressive tariffs, which could stall progress if unresolved. With a balanced, apolitical lens, this episode offers candid insights into why policy matters for biotech investors, operators, and dealmakers—and what to watch for as 2025 unfolds. Tune in to understand the key inflection points and why Geoff sees the second half of 2025 as a potential breakout period for the industry. Full Transcript: Welcome to Biotalk. My name is Geoff Meyerson, CEO and Co-founder of Locust Walk, and you are listening to Biotalk, our podcast for biotech deal makers. In this episode, I want to zoom out and talk about the bigger picture — what's really driving the biotech market right now. In almost every meeting the past few months I have been asked my views on the market.  I decided that I am going to share my thoughts publicly. I fancy myself to be a free market limited government champion across all aspects of life. I do not comment politically nor believe it is my job to criticize or promote any politician or party. That said, the macro policies enacted by both parties directly impact the biopharma industry, and I believe it's important to analyze and comment on areas related to the life science industry. For all other issues, I subscribe to the University of Chicago's institutional neutrality, and it is my (and Locust Walk's) policy to not comment publicly. First a recap of why I was bearish starting fall 2021 when Locust Walk ran a webinar titled “Has Biotech Peaked”. Throughout 2022, 2023, and until September 2024, despite many market analysts predicting a turnaround, I maintained my bearishness because the 3 underlying headwinds that started blowing hadn't stopped or reversed, namely: Regulatory headwinds because of the IRA Transaction headwinds from an openly hostile FTC Monetary headwinds via high interest rates caused by high inflation Until these 3 drivers reversed, I didn't believe the market would improve beyond incremental changes. When in September 2024 the US Federal Reserve dropped rates by 50 bps, the rate tightening cycle had not only stopped but reversed. My changing perspective was independent of the pending election since the largest factor interest rates was starting to shift. In January 2025, Lina Khan exited the FTC and a new era of antitrust enforcement began. While far from perfect, it has been markedly more pro-business with a much less aggressive effort to block transactions. Locust Walk's Quarterly Market conditions detailed a 47% uptick in M&A by value and 35% by volume showing signs of life in this market even though I didn't anticipate any material improvement until 2H25 because it takes time for deals to come to fruition after the changeover in policy. I predicted M&A had the potential to transform the industry this year after years of suppression. I stand by this prediction and for everyone's sake I hope I'm right. The IRA pill fix is being discussed and because President Trump has come out in support, some form of it is likely to make its way into the reconciliation package of tax and regulatory cuts. I hope small molecules move to 13 years of exclusivity but bigger price discounts thereafter to remain budget neutral rather than meeting in the middle at 11 years, which I think would be quite problematic.

Pharma Intelligence Podcasts
Scrip M&A Podcast: Will the FDA Staff Cuts Affect Biopharma M&A Activity?

Pharma Intelligence Podcasts

Play Episode Listen Later May 1, 2025 40:27


Scrip senior writer Joseph Haas discusses the potential impact of the recent FDA staff cuts with attorneys Andrew Goodman of Paul Hastings LLP and Alan Minsk of Arnall Golden Gregory, as well as Naya Therapeutics CEO Daniel Teper

Lean By Design
0201. From Small Wins to Organizational Transformation: Building Momentum in Biopharma

Lean By Design

Play Episode Listen Later Apr 30, 2025 45:00 Transcription Available


Send us a textIn this episode, we explore how small, intentional improvements—not sweeping changes—drive real progress in biopharma operations. The discussion highlights a common challenge: the disconnect between strategy and execution, often due to underutilized middle management.You'll learn a simple framework for creating meaningful change: start within your sphere of influence, map key inputs and outputs, and implement solutions that reduce effort while increasing visibility. Small wins in project management can build momentum, leading to better accountability, decision-making, and resource allocation.The conversation also covers the importance of tools and training—many organizations have powerful software but lack the support to maximize its potential. The takeaway? Improve your own workflows first to build credibility before driving broader change.Ready to assess your organization's efficiency? Connect with us at leanbydesign@sigmalabconsulting.com to uncover high-impact improvement opportunities.

BioCentury This Week
Ep. 292 - Myasthenia Gravis Spotlight & AACR Preview

BioCentury This Week

Play Episode Listen Later Apr 26, 2025 25:51


Biopharma companies are vying to dethrone Vyvgart as a leading therapy for myasthenia gravis, with the latest data for therapies treating the rare autoimmune neuromuscular disease coming at this month's American Academy of Neurology. On a special episode of the BioCentury This Week podcast, BioCentury's editors discuss the landscape for MG therapies, including anti-BLyS and APRIL therapy telitacicept from Remegen. Joining BioCentury's editors are Qing Zuraw, chief development officer of podcast sponsor RemeGen, and Amit Sachdev, PI on global trials of the biotech's therapy. BioCentury's editors also preview the American Association for Cancer Research annual meeting, where degraders and bispecifics are defining translational trends at this year's event. This episode of BioCentury This Week podcast was sponsored by RemeGen.View full story: https://www.biocentury.com/article/655751#biotech #biopharma #pharma #lifescience #AAN #AACR00:01 - Sponsor Message: RemeGen Co.01:02 - Myasthenia Gravis at AAN08:31 - RemeGen's Telitacicept18:03 - AACR: Targets and TrendsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Lab Rats to Unicorns
Building Biotech at the Interface: Geoff Duyk on Genomics, Platforms, and Grove Biopharma_e.67

Lab Rats to Unicorns

Play Episode Listen Later Apr 24, 2025 83:34


In this episode of Lab Rats to Unicorns, host John Flavin speaks with Dr. Geoff Duyk, co-founder and CEO of Grove Biopharma. Geoff brings over 35 years of experience across academia, biotech leadership, and venture capital. From his early work in human genetics at UCSF to co-founding Millennium Pharmaceuticals and leading R&D at Exelixis, Geoff unpacks the evolution of biotech from the 1970s to today. This conversation comes on the heels of Grove's massive $30M Series A. Geoff shares the story behind Grove Biopharma's founding, born from a collaboration between a Northwestern chemist, a green chemistry innovator, and himself—culminating in a startup focused on intracellular targets using novel protein-mimetic polymers. Geoff also reflects on the infrastructure and cultural foundations that make biotech innovation possible, from the NIH's visionary investments to the importance of people, timing, and place. Learn how Grove is challenging the limits of drug design with a new class of molecules that behave like antibodies but operate inside cells—unlocking new frontiers in cancer and beyond.

Biotalk
Episode 26: Asia’s 2025 Q1 Report: Global Trends in Biopharma Transactions

Biotalk

Play Episode Listen Later Apr 16, 2025 10:38


During the Asia-focused Episode 26 of Biotalk, Geoff Meyerson, CEO of Locust Walk, shares fresh insights from Japan, China, and Korea, as featured in our 2025 Q1 Report: Global Trends in Biopharma Transactions Report.  Japan saw modest market recovery, a $3.3B buyout of Mitsubishi Tanabe, and lighter licensing activity. Early-stage financings picked up as investors re-engaged. China shifted from IPO optimism to global deal-making as markets cooled. Notable trends included strong out-licensing ($17.6B), AstraZeneca's $2.5B investment, and Ascentage's NASDAQ debut backed by Takeda. Venture activity rebounded, driven by insider-led late-stage rounds. Korea drew attention with Orum's IPO, early-stage deals, and a growing focus on CDMO by major players.Listen now to gain insights into the evolving global biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.

Biotalk
Biotalk Episode 25: 2025 Q1 Report: Global Trends in Biopharma Transactions

Biotalk

Play Episode Listen Later Apr 16, 2025 13:17


During Episode 25 of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2025 Q1 Report: Global Trends in Biopharma Transactions Report, covering capital markets, strategic deals, and regional trends. Market Overview: The XBI fell 14% YoY, underperforming the NBI. Biotech weakness stemmed from tariff fears, FDA turnover, and HHS layoffs—pressuring small caps. Capital Markets: Capital raised dropped 33% from Q4. IPOs briefly reopened—large caps gained, small caps declined. Follow-ons fell 60%. PIPEs were weak, except Immunovant's $450M. Venture: Slight dip from Q4 but ahead of all 2023 quarters. Late-stage rounds led, with 11 mega-rounds (Eikon $351M, Kardigan $300M) making up over half the total. M&A & Licensing: M&A hit $25.2B across 13 deals, focused on Ph2+ assets (e.g., J&J/Intra-Cellular). Licensing stayed strong, favoring clinical-stage programs. Europe: Strategic deal value reached $13B, led by Zealand-Roche and Gubra-AbbVie. Venture hit $1.2B—90% in Series A rounds like Verdiva ($411M) and Windward ($200M). Outlook: Regulatory uncertainty and rates may delay M&A, though late-stage and commercial deals could gain momentum. Listen now to gain insights into the evolving biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you.

The Vox Markets Podcast
2078: Q&A with IXICO CEO Bram Goorden

The Vox Markets Podcast

Play Episode Listen Later Apr 16, 2025 8:59


Watch on YouTube In this fascinating interview, CEO Bram Goorden of  IXICO - an AI powered medical imaging analytics firm helping Biopharma groups develop new treatments for neurodegenerative diseases – kindly takes me through today's inline H1'25 trading update and positive outlook. Disclosure: I own shares in IXICO, who is also a Vox Markets client.

Pharma and BioTech Daily
Boosting US Biotech and Battling China: A Daily Dose of Pharma News

Pharma and BioTech Daily

Play Episode Listen Later Apr 14, 2025 1:10


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Lawmakers are focusing on boosting the US biotech industry while keeping China's growth in check. Novartis plans to invest $23 billion in US operations, potentially creating up to 1,000 new jobs. The FDA is exploring the use of AI and human 'organoid' lab models to replace some animal testing. The current tariffs and layoffs in the biopharma industry under the Trump administration have created uncertainty. Experts are advising companies to optimize process development for gene therapy products. Biopharma professionals are engaging in discussions on how nonprofit organizations can drive healthcare innovation amidst significant industry layoffs, such as Opthea cutting 65% of staff and Pfizer cutting 56%. The recent tariff pause by Trump has led to a late-day rally for pharma stocks. upcoming events include webinars on AI, regulation, and drug development laws, as well as strategies for surviving in the biotech downturn. Biotech leaders are calling on Senator Cassidy to address FDA cuts that could potentially set the US back 35 years.

The Top Line
Q1 biopharma layoff trends, plus expectations for Q2

The Top Line

Play Episode Listen Later Apr 11, 2025 11:29


In this week’s episode of "The Top Line," Fierce Deputy Editor Andrea Park and Fierce Biotech Senior Editor Gabrielle Masson discuss how workforce reductions impacted the biopharma industry in the first quarter. The pair examine industry trends, company closures, developments in the cell and gene space—and the reductions in force happening at federal health agencies alongside them. To learn more about the topics in this episode: Biopharmas laid off staffers at least 63 times in Q1: Fierce Biotech analysis Fierce Biotech Layoff Tracker 2025: Pfizer sells site, cuts staff; Opthea reduces workforce by 65% See omnystudio.com/listener for privacy information.

Touching Base
Discussing De-Extinction, Trump's Tariffs Touch Biopharma, and Reports from Recent Travels

Touching Base

Play Episode Listen Later Apr 11, 2025 45:26


Are Dire Wolves really back? We give our take on Colossal Biosciences' latest announcement about the de-extinction of Dire Wolves including some thoughts on their approach and some of the broader implications of their work. In other stories, we discuss the early impact of the Trump administration's tariffs on biotech as well as the growing alarm in the scientific community in the wake of sweeping layoffs and leadership departures at the FDA, CDC, and NIH. We also share news from recent scientific conferences and meetings that we've attended as well as an interesting study that used human cell maps to shed new light on pediatric bone cancer.Join GEN editors Corinna Singleman, PhD, Alex Philippidis, Fay Lin, PhD, and Uduak Thomas for a discussion of the latest biotech and biopharma news. Listed below are links to the GEN stories referenced in this episode of Touching Base.Plex Research Partners with Ginkgo Bioworks to Apply AI-Based Search Engine to Drug DiscoveryBy Uduak Thomas, GEN, April 8, 2025 Danaher-IGI Beacon for CRISPR Cures Celebrates One-Year AnniversaryBy Fay Lin, PhD, GEN, March 28, 2025Human Cell Maps Uncover Insights in Pediatric Bone Cancer By Fay Lin, PhD, GEN, April 10, 2025StockWatch: Biopharma Funds Tumble with Wall Street as Industry Spared from Worst of Tariffs—for NowBy Alex Philippidis, GEN Edge, April 6, 2025 FDA, NIH, CDC Stagger as HHS Axe Falls, Eliminating 10,000 JobsBy Alex Philippidis, GEN Edge, April 1, 2025 Industry Voices Alarm as Peter Marks Departs FDABy Kevin Davies, PhD, and Alex Philippidis, GEN Edge, March 30, 2025The State of Multiomics & NGS 2025Broadcast Date: Wednesday, April 23, 2025 Resurrection Genomics: A Conversation with Colossal's Chief Biology Officer Eriona HysolliThe State of Omics 2024, April 17, 2024 Hosted on Acast. See acast.com/privacy for more information.

The Biotech Startups Podcast

"Focus and commitment to niche ideas have huge payoffs." In part four of our conversation with Alfredo Andere, co-founder of LatchBio, we explore how the company evolved from a simple workflow orchestrator into a comprehensive platform serving biopharma companies and solution providers. Alfredo shares his approach to enterprise sales, emphasizing the importance of speed, focus, and building strong relationships with customers. He also delves into his philosophy on fundraising and the pivotal role of iterative development in creating impactful biotech solutions. Alfredo reflects on the challenges and rewards of working in niche markets, explaining why deep commitment and loyalty to specific problems are essential for long-term success. Whether you're a first-time founder or an experienced entrepreneur, this episode is packed with actionable insights on building, selling, and scaling in the biotech space.

The Agenda with Steve Paikin (Audio)
What is the Future of Canadian Manufacturing?

The Agenda with Steve Paikin (Audio)

Play Episode Listen Later Apr 10, 2025 34:53


Canada's manufacturing sector faced challenges even before President Donald Trump imposed tariffs on goods made here. The overall sector has shrunk, both in its contribution to our economy, and the number of workers it employs. So, how should Canada support existing companies and their workers as tariffs take hold? And what's the way forward to building up a homegrown manufacturing sector that provides higher-skilled jobs and in-demand goods? See omnystudio.com/listener for privacy information.

Pharma and BioTech Daily
Pharma and Biotech Daily: Tensions, Trials, and Triumphs in the Industry

Pharma and BioTech Daily

Play Episode Listen Later Apr 4, 2025 0:42


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. Pharma industry tensions rise as Trump tariffs miss sector for now. FDA's interim CBER head appointed after key resignation. Xaira Therapeutics hires top AI academic. Novavax's COVID-19 shot review deadline missed by FDA. Trilink offers guide RNA for CRISPR workflow. Biotech sector sees investment surge. Beigene scraps candidate, Sarepta's gene therapy on hold in Europe. Biopharma professionals work long hours.In other news, there are safety concerns in Duchenne treatment. Democrats challenge Trump health cuts. And there are job opportunities in the biopharma industry.

BioSpace
FDA on Fire, Novo's Mixed Bag of Semaglutide Cardio Data, Kisunla's EU Miss, More

BioSpace

Play Episode Listen Later Apr 2, 2025 17:34


Biopharma's reaction to the forced resignation of venerable CBER director Peter Marks has been swift and furious, with former FDA Commissioner Robert Califf saying on LinkedIn that “the FDA as we've known it is finished.” Analysts, meanwhile, called Marks' exit “arguably biotech investors' greatest fear,” as company shares across the industry tumbled.   Marks' announcement added insult to injury for the agency, which was already reeling from the announced cuts of 10,000 employees across the Department of Health and Human Services, including 3,500 FDA staffers. Those layoffs began to roll out on Tuesday as some employees showed up to work only to discover they no longer had a job. Amid all this chaos, Cantor Fitzgerald analysts called for Kennedy himself to get the axe, saying in part that he was “undermining the trusted leadership of health care in this country.”    Despite the turmoil, drug development continues in the obesity space, with Novo Nordisk presenting mixed data from its semaglutide franchise at the American College of Cardiology's annual conference last weekend. While an oral version of the blockbuster drug showed cardiovascular benefits for some patients, it failed to change the trajectory of other major adverse cardiovascular events. Meanwhile, Novo continues its battle against compounding pharmacies manufacturing copycat versions of semaglutide—as multiple players scramble for a piece of this massive pie.    On the Alzheimer's front, Eli Lilly's Kisunla failed last week to win the recommendation of the EU's Committee for Medicinal Products for Human Use. This decision is consistent with CHMP's recent stance on anti-amyloid antibodies, as Biogen and Eisai have also struggled to get Leqembi approved in Europe.    On a positive note, pharma R&D returns grew again in 2024, but Deloitte warned that this progress is “fragile.” The firm urged companies to be bold and embrace cutting edge technology like gene therapy and AI. These returns can't help everyone, however, as the past week has seen an uptick in layoffs across biopharma, including at Carisma Therapeutics, Organon and Tenaya Therapeutics.   Finally, as April kicks off cancer conference season, BioSpace took a deep dive into the recent action in the always-hot in radiopharmaceuticals space.  

Artificial Intelligence in Industry with Daniel Faggella
AI in Biopharma Innovation and Regulatory Challenges - with Nishtha Jain of Takeda Pharmaceuticals

Artificial Intelligence in Industry with Daniel Faggella

Play Episode Listen Later Mar 25, 2025 26:36


Today's guest is Nishtha Jain, Head of Innovation and Digital Technology at Takeda Pharmaceuticals. Nistha returns to the program to discuss the transformative impact of AI across the pharmaceutical value chain. She and Emerj Editorial Director Matthew DeMello explore how AI is improving drug development efficiency, addressing data challenges, and overcoming regulatory hurdles. She highlights key breakthroughs like Google DeepMind's AlphaFold and AI-assisted clinical trial optimization, emphasizing the potential for faster, more cost-effective drug development. The discussion also covers the challenges of AI adoption, including data accessibility, regulatory compliance, and ethical considerations like bias in AI models. If you've enjoyed or benefited from some of the insights of this episode, consider leaving us a five-star review on Apple Podcasts, and let us know what you learned, found helpful, or liked most about this show!

AGORACOM Small Cap CEO Interviews
Canadian Small Cap Quantum BioPharma on The Verge of Multiple Sclerosis Breakthrough

AGORACOM Small Cap CEO Interviews

Play Episode Listen Later Mar 25, 2025 20:44


KEY MILESTONES AND WHAT'S NEXTSuccessful Phase 1 Trial: Lucid-MS has shown excellent safety with no serious side effects, paving the way for a groundbreaking treatment for MS.Next Major Step: The Phase 2 trial is set for early 2026, with 60 participants.FDA Submission on the Horizon: Plans to submit application to the FDA by late 2025, taking a huge step toward regulatory approval.Massive Market Opportunity: With 2.9 million people worldwide affected by Multiple Sclerosis and the market projected to surpass $30 billion by 2030, Lucid-MS could potentially capture a significant share of this rapidly expanding space.A NEW ERA IN MULTIPLE SCLEROSIS TREATMENTQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Lucid-MS is setting the stage to revolutionize MS treatment. Unlike existing therapies that only target immune system responses, Lucid-MS focuses on protecting and repairing myelin, the critical layer around nerve fibers. This novel approach has the potential to slow or even reverse disease progression—offering new hope for millions of MS sufferers.Think of nerves like electrical wires in your body, and myelin as the protective coating around those wires. With Multiple Sclerosis, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.HOW DOES IT WORK? A TOTALLY NEW APPROACH TO TREATING MSThink of nerves like electrical wires in your body, and myelin as the protective coating around those wires. With Multiple Sclerosis, the immune system attacks this coating (called demyelination), causing damage that leads to muscle weakness, vision problems, and difficulty moving.Most MS treatments try to calm the immune system to slow down the attack. Lucid-MS is different. Instead of focusing on the immune system, it works directly on the myelin to stabilize and protect it from damage.WHY IS THIS IMPORTANT?By keeping myelin intact, Lucid-MS may help slow down the progression of MS and prevent disability—something current MS drugs don't do very well.SCIENTIFIC BREAKTHROUGH BACKED BY INDUSTRY RECOGNITIONLucid-MS is backed by cutting-edge research from Dr. Lakshmi Khotra's lab at the University of Toronto, where the critical process of myelin breakdown in MS patients was discovered. The drug's ability to address this underlying issue is a potential game-changer in neurodegenerative treatments.It's already gaining enthusiastic support from leading medical experts and researchers, underscoring its transformative potential.A VISION FOR THE FUTUREDr. Andrzej Chruscinski, Vice President of Scientific and Clinical Affairs at Quantum BioPharma, expressed the company's excitement about Lucid-MS's future.“We are on the cusp of something monumental. Lucid-MS has the potential to transform MS treatment and open doors for treating other nerve-related diseases. As we move toward Phase 2 and beyond, we're excited to bring this innovative therapy to the patients who need it most.”With promising clinical results, a massive market opportunity, and rising industry recognition, Quantum BioPharma is leading the charge in next-generation treatments for Multiple Sclerosis 

Axial Podcast
AI Workflows for Biopharma with Alex Telford

Axial Podcast

Play Episode Listen Later Mar 23, 2025 57:33


Alex Telford is the Co-Founder and CEO of Convoke.

Molecule to Market: Inside the outsourcing space
From astrophysicist to biopharma industry leader

Molecule to Market: Inside the outsourcing space

Play Episode Listen Later Mar 21, 2025 54:53


In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Ben Locwin, Chief Scientist, Head of Clinical Services and Project Sciences at Black Diamond Networks (BDN). Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Ben, covering: Being part of the Lonza growth story in its 'scrappy' years Learning never to say no to a good opportunity and how that's opened many doors Becoming part of the more significant patient conversations at Biogen Dropping in seal teams to help companies do what they may never have achieved Why is change always inevitable in our sector, and what may the future hold for us all? As the saying goes, we're all a product of our growth and past experiences. Ben Locwin is an industry and healthcare executive who has been variously described as a "Remarkably talented speaker" by the Association for Talent Development, a "Rockstar epidemiologist" by NPR, a "healthcare futurist" by Contract Pharma and Rodman Media, and "a good friend" by ...his friends. He began his journey as an astrophysicist 30 years ago and then transitioned into the world of biotech in the 1990s when the nascent industry was yet poised to take over the world. He has specialized training as a neuroscientist and has worked with some of the top companies in the industry, both as a leader and a consultant. He has been a member of several Boards, association committees, steering teams, Task Forces, and scientific advisory panels. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

Pharma and BioTech Daily
Pharma and Biotech Daily: A Roundup of Key Industry News and Developments

Pharma and BioTech Daily

Play Episode Listen Later Mar 18, 2025 1:56


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.AstraZeneca has recently made a significant investment of up to $1 billion in cell therapy through the acquisition of esobiotec. This move is part of AstraZeneca's larger strategy to expand in the cell therapy space, positioning itself to be a major player in the market. Dyne is also looking to file for accelerated approval for its Duchenne exon skipping oligomer, while Taiho Pharmaceutical has acquired ADC partner Araris for up to $1.1 billion. Alnylam is expected to enter the transthyretin amyloid cardiomyopathy market, which is projected to reach $11.2 billion by 2030.Sino Biological has developed reagents for the 2025-2026 influenza vaccine strains, offering a range of recombinant proteins for vaccine development. The pharmaceutical industry is seeing significant activity in various therapy areas, with companies making strategic investments and advancements in research and development.Alnylam is awaiting approval for their drug Amvuttra in the transthyretin amyloid cardiomyopathy market, which is currently dominated by Pfizer and BridgeBio. The obesity drug market is becoming increasingly competitive, with companies focusing on overall health benefits rather than just weight loss. Biopharma companies are now exploring the use of CAR T cell therapies for autoimmune disorders, with several readouts expected this year. Ionis and Ultragenyx are competing to develop treatments for Angelman syndrome, while Neuren is trying to catch up.Overall health outcomes are becoming more important in the obesity drug market, with successful studies in therapeutic areas like cardiovascular and sleep apnea providing a market advantage. Other news includes flu vaccine recommendations from the FDA and updates on drugs for alcohol use disorder, plaque psoriasis, breast cancer, and weight loss. The biopharma industry continues to evolve, with readers encouraged to provide suggestions for future coverage topics.

The Entrepreneur Experiment
EE 406 - From Idea to Impact: The Courage to Start Your Own Business with Keogh's Crisps & Advanced Cosmoetics

The Entrepreneur Experiment

Play Episode Listen Later Mar 6, 2025 66:12 Transcription Available


The Entrepreneur Experiment Live Special with The Local Enterprise Offices: Lessons from Ireland's Top Founders. To celebrate Local Enterprise Week, we sit down with Tom Keogh of Keogh's Crisps and Noreen Hackett of Advanced Cosmetics to uncover the real stories behind building globally recognised brands from Ireland. Tom shares how his family farm transformed from market gardening to a premium snack brand sold in over 20 countries, including on international airlines. Noreen reveals how she went from chemist to CEO, creating an end-to-end cosmetics manufacturing powerhouse serving 37 brands worldwide.  If you're a founder or aspiring entrepreneur, this episode is packed with real-world insights on branding, scaling, and navigating sustainability and global expansion.

Oral Arguments for the Court of Appeals for the Federal Circuit

uniQure Biopharma B.V. v. Pfizer Inc.

Bio from the Bayou
Episode 76: How to Partner with Global Biopharma Companies, featuring Industry Expert Lidia Sobków

Bio from the Bayou

Play Episode Listen Later Mar 5, 2025 19:48


How can startups and academic institutions successfully collaborate with a global biopharmaceutical company? In this episode, host James Zanewicz, JD, LLM, RTTP, sits down with Key Opinion Leader Lidia Sobków, PhD, Senior Manager of Technology Licensing & Collaborations at AbbVie, to discuss how her team identifies cutting-edge research and partners with academic institutions and biotech startups to drive innovation. From securing collaborations to leveraging industry consortia, Lidia shares invaluable insights on how to position your research for success with major pharmaceutical companies. In this episode, you'll discover: What AbbVie looks for in potential partners and how universities and startups can stand out. The role of consortia in fostering industry-academic collaboration for groundbreaking research. Real-world examples of successful partnerships that have advanced neuroscience and imaging technologies. Tune in to learn how to navigate industry partnerships and make an impact in the biotech ecosystem! Links: Connect with Lidia Sobków, PhD, and learn more about AbbVie. Connect with James Zanewicz, JD, LLM, RTTP and learn about Tulane Medicine Business Development and the School of Medicine. Check out The Michael J. Fox Foundation and Critical Path Institute. Check out Gedeon Richter and Enigma Biomedical Group. Check out BIO on the BAYOU and make plans to attend October 28 & 29, 2025. Learn more about BIO from the BAYOU - the podcast. Bio from the Bayou is a podcast that explores biotech innovation, business development, and healthcare outcomes in New Orleans & The Gulf South, connecting biotech companies, investors, and key opinion leaders to advance medicine, technology, and startup opportunities in the region.

The MM+M Podcast
Walgreens pushes ahead on trial diversity

The MM+M Podcast

Play Episode Listen Later Feb 28, 2025 54:58


Walgreens' Ramita Tandon, chief clinical trials officer, explains how the pharmacy chain is working with biopharma to enhance research inclusivity amid ongoing challenges to DEI on the federal and corporate level, in a conversation with MM+M's Heerea Rikhraj. For our Trends segment, we'll discuss what the end of the semaglutide shortage means for Hims and Hers and other telehealth firms that have been selling compounded versions of GLP-1 drugs, as well as how RFK Jr. is harnessing the CDC's comms apparatus to further his MAHA agenda.Music by Sixième Son Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.

Pharma and BioTech Daily
Pharma and Biotech Daily: The Latest in Industry News and Trends

Pharma and BioTech Daily

Play Episode Listen Later Feb 20, 2025 2:03


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. A lawsuit against Merck related to the HPV vaccine Gardasil, led by Robert F. Kennedy Jr., has been suspended after confirmation. Biopharma bankruptcies are at a peak, with 14 companies filing for chapter 11 protection in 2023 and numbers remaining high in 2024. Gilead has passed on an option for a cancer drug from Arcus, and Merck has partnered with Epitopea to identify unknown tumor antigens. The American Biomanufacturing Summit is set to take place in April 2025 in San Francisco, bringing together industry leaders for exclusive sessions and networking opportunities. The pharmaceutical industry is facing challenges such as patent cliffs and regulatory changes, with companies like Exelixis looking to next-generation cancer drugs for growth. Novo is seeking $830 million in a fraud case against a Singaporean biotech company over a kidney drug. Additionally, there are insights on site survival for clinical research sites and how biotechs can avoid state and local tax surprises. Trump's administration is reportedly seeking to dismantle parts of the FDA workforce, leading to concerns about job security within the agency.Biopharma bankruptcies remained high in 2024, with 14 companies filing for chapter 11 protection, the most in over a decade. Cour Pharmaceuticals solidified its mission last year with a series a raise. Some biotechs are facing unexpected tax consequences when dealing with big pharma. Several top pharma companies are facing massive patent cliffs, including Merck's Keytruda. Novo seeks $830 million in a fraud case against a Singaporean biotech, while Exelixis looks to next-gen cancer drugs. Biogen and Stoke strike a co-development deal for Dravet syndrome. The FDA faces uncertainty as the Trump team seeks to dismantle the workforce. Aardvark Therapeutics raises $94 million for obesity treatments. Abbott, Life Edit Therapeutics, and Regeneron Pharmaceuticals are hiring for various positions.

Austin Next
Rewriting Biopharma's Playbook with Mallory Factor, Founder and CEO IntraBio

Austin Next

Play Episode Listen Later Feb 19, 2025 49:25


A unicorn biopharma that ignores the traditional playbook, breaks development speed records, and chose Austin over the traditional biotech hubs.  Mallory Factor, Founder and CEO of IntraBio, joins us to share how his Oxford-born company created an FDA-approved drug in record time while doing everything differently. In this wide-ranging conversation, we explore how finding unconventional talent, maintaining ruthless focus, and embracing a different mindset has led to transformational success in an industry resistant to change. Episode HighlightsBuilding a Different Kind of Biopharma CompanyBreaking Speed Records in Drug DevelopmentFinding Unconventional TalentChallenging Traditional Pharma ThinkingWhy Austin Over Boston and San FranciscoThe Power of Focus in Drug DevelopmentAustin's Creative Collisions and FutureWhat's Next Austin?"Austin has some political problems that's going to have to clear up to make it a better city. Hopefully in time it will and it'll catapult it into the top five, six cities in America"Mallory Factor, IntraBio, Aqneursa -------------------Austin Next Links: Website, X/Twitter, YouTube, LinkedInEcosystem Metacognition Substack

Off Script: A Pharma Manufacturing Podcast
Novartis boosts Slovenia investment to $3.6B, Trump tariffs could unsettle biopharma FDI, FDA warns Global Calcium, blocks US imports [The good, the bad, the ugly]

Off Script: A Pharma Manufacturing Podcast

Play Episode Listen Later Feb 18, 2025 4:24


Join us each week as we do a quick review of three compelling stories from the pharma world — one good, one bad and one ugly. Up this week:   The good — Novartis boosts Slovenia investment to $3.6B The bad — Trump tariffs unsettle biopharma FDI The ugly — FDA warns Global Calcium, blocks US imports

Pharma and BioTech Daily
Pharma and Biotech Daily: Navigating the Latest Industry Shifts and Innovations

Pharma and BioTech Daily

Play Episode Listen Later Feb 18, 2025 1:05


Good morning from Pharma and Biotech Daily, the podcast that gives you only what's important to hear in the Pharma and Biotech world. The Trump administration's staffing purge has now impacted the FDA, leading to layoffs of employees after Robert F. Kennedy Jr.'s confirmation as HHS secretary. Despite these changes, vaccine approvals are still progressing as usual.Biopharma companies are making significant investments in immunology and inflammation research, focusing on finding new targets and pathways for diseases like inflammatory bowel disease and atopic dermatitis. The FDA has recently approved multiple vaccines back-to-back, even as Kennedy, known for his vaccine skepticism, assumes a leadership role at the HHS.In other news, the American Biomanufacturing Summit is scheduled for April 2025, offering industry leaders a platform for networking and informative sessions. Updates in the psychedelics space, biosimilar approvals, and recent layoffs at Kojin impacting 25 employees are also making headlines.Opportunities in the biopharma industry continue to grow, with job openings highlighted in the newsletter.

Molecule to Market: Inside the outsourcing space
Biopharma Global Supply veteran

Molecule to Market: Inside the outsourcing space

Play Episode Listen Later Feb 14, 2025 55:43


In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Robert Bottome, a global supply veteran. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Robert, covering: Stretching yourself by tapping into the collective wisdom of others The challenge of pairing internal production capacity with the need for agile, rapid early phase R&D The decision to leave Genentech to do a 'do over' and do things better at a growing biotech company Why strategic partnerships are easy on a PowerPoint but hard to realize in practice fully Now retired, Robert is an accomplished and results-driven supply chain and operations leader with extensive experience overseeing and driving global supply chain operations and operational efficiency for organizations in the biotechnology and pharmaceutical industries (including Genentech and BioMarin). He has experience managing end-to-end supply chain functions, including global logistics, production planning, trade compliance, and product launches. He has a background in transforming cross-functional teams and implementing strategic initiatives optimizing production schedules, reducing cycle times, and improving supply resilience. Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating! Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

pharmaphorum Podcast
Defining, building, and implementing in the next wave of biopharma R&D

pharmaphorum Podcast

Play Episode Listen Later Feb 13, 2025 25:27


In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with two PharmaLex experts about navigating complex R&D processes to unleash the next wave of biopharma breakthroughs. PharmaLex's Dr Christian Schneider, VP & Chief Medical Officer, Clinical Development Services, together with Dr Christelle Boileau, Director of Regulatory Development Strategy and IPD solution lead at PharmaLex, which is part of Cencora, explore the many challenges faced across the clinical trial landscape when it comes to new therapies, including ATMP development. From preclinical to market access and regulatory considerations, Dr Boileau warns that development is not a linear process, and for both an early-as-possible strategy is paramount. Comparing classical paradigms with the new, traditional endpoints need to be reassessed – for example, when defining dosage – says Dr Schneider. You can listen to episode 165a of the pharmaphorum podcast in the player below, download the episode to your computer, or find it - and subscribe to the rest of the series - in iTunes, Spotify, Amazon Music, Podbean, and pretty much wherever you get your other podcasts!

The Long Run with Luke Timmerman
Ep173: Robert Blum on Building a Fully Integrated Biopharma For Muscle Disorders

The Long Run with Luke Timmerman

Play Episode Listen Later Feb 11, 2025 57:56


Robert Blum, CEO of South San Francisco-based Cytokinetics, on building a fully integrated biopharma to treat muscle disorders.

Pharma and BioTech Daily
Pharma and Biotech Daily: Navigating the Latest in Industry Trends and Challenges

Pharma and BioTech Daily

Play Episode Listen Later Feb 6, 2025 1:40


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Novo Nordisk's drug Wegovy saw a significant increase in sales in 2024, but analysts are still not satisfied and are questioning why the company can't access more patients, especially in the U.S. Despite this success, there is a lack of female leadership in new biotech companies, with only nine out of 102 launches having a woman at the helm. In other news, GlaxoSmithKline is looking to make deals in the cancer, respiratory, and inflammation sectors, while Valerio is facing financial challenges and has had to cut operations. The biotechnology industry is facing a shift towards more data integration and an increase in mergers and acquisitions.Women leaders in biotech are declining as new company founders prioritize CEOs with a proven track record. Out of the 102 most recent company launches or financings, only nine had a woman at the helm. The lack of women in leadership roles in biopharma continues to be a recurring issue. Biopharma companies are investing more in licensing deals to enrich their pipelines with novel therapies, with a focus on combating patent expirations and generics. Despite challenges, such as a shortage of skilled operators, training programs are being emphasized to upskill teams effectively. Some top biopharma licensing deals of 2024 are highlighted, along with updates on various companies' earnings and strategic moves. The Biotech Sisterhood aims to provide fellowship among women leaders in the industry, showcasing a group of women and allies as their authentic selves at events like the J.P. Morgan Healthcare Conference. Additionally, the newsletter includes job listings and opportunities for industry professionals to stay informed and engaged.

The Top Line
What to expect from the biotech IPO market in 2025

The Top Line

Play Episode Listen Later Jan 31, 2025 34:06


During a panel discussion at this year’s Fierce JPM Week—which took place alongside the annual J.P. Morgan Healthcare Conference in San Francisco—industry experts broke down what it takes to pull off a successful biotech IPO in the current market. This week’s episode of The Top Line dives into the discussion, featuring Fierce Biotech’s Gabrielle Masson as moderator, joined by Septerna CEO and co-founder Jeffrey Finer, M.D., Ph.D.; Rapport Therapeutics Chief Financial Officer Troy Ignelzi; Sofinnova Investments General Partner Maha Katabi, Ph.D.; and Morgan Stanley Executive Director Chirag Surti. In their wide-ranging conversation, the industry leaders spoke about the types of biotechs that debuted on the public market in 2024, the keys to success for an effective IPO and what to expect from the market heading into 2025. To learn more about the topics in this episode:   ‘A really rational IPO environment’: What does it takes for a biotech to go public now? 'Own JP Morgan, don't let JP Morgan own you': Biopharma—and Jill Biden—show up for JPM25 Septerna's $288M IPO is another sign of the market warming to biotech investment Third Rock's Rapport reveals upsized $154M IPO This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.See omnystudio.com/listener for privacy information.

Mission Matters Podcast with Adam Torres
Nasdaq-listed Quantum BioPharma R&D Focused Business, Developing Solutions and Treatments

Mission Matters Podcast with Adam Torres

Play Episode Listen Later Jan 30, 2025 18:45


Quantum BioPharma is developing a portfolio of products including Quantum's Lucid-MS drug development and their drink, unbuzzd. In this episode, Adam Torres and Jason Sawyer, Head of Finance & M&A at Quantum BioPharma, explore Quantum BioPharma. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia

Mission Matters Innovation
Nasdaq-listed Quantum BioPharma R&D Focused Business, Developing Solutions and Treatments

Mission Matters Innovation

Play Episode Listen Later Jan 30, 2025 18:45


Quantum BioPharma is developing a portfolio of products including Quantum's Lucid-MS drug development and their drink, unbuzzd. In this episode, Adam Torres and Jason Sawyer, Head of Finance & M&A at Quantum BioPharma, explore Quantum BioPharma. Follow Adam on Instagram at https://www.instagram.com/askadamtorres/ for up to date information on book releases and tour schedule. Apply to be a guest on our podcast: https://missionmatters.lpages.co/podcastguest/ Visit our website: https://missionmatters.com/ More FREE content from Mission Matters here: https://linktr.ee/missionmattersmedia Learn more about your ad choices. Visit podcastchoices.com/adchoices

The Athletics Of Business
Game-Changing Leadership: Brian Grawer's Secrets to Biopharma Success

The Athletics Of Business

Play Episode Listen Later Jan 29, 2025 52:10


In this engaging episode, Brian Grawer shares his inspiring journey from being a standout basketball player at the University of Missouri to leading successful sales teams in the highly competitive pharmaceutical industry. With a unique perspective shaped by his athletic background, Brian discusses the parallels between sports and business, offering practical insights into leadership, team building, and personal growth. Brian opens up about the values instilled in him through basketball, such as preparation, discipline, and coachability, and how these lessons have guided him in fostering authentic leadership and cultivating high-performing teams. Whether you're an athlete, a business professional, or a leader looking to inspire your team, this episode is packed with actionable advice and thought-provoking reflections. Our Guest Brian Grawer's leadership journey is rooted in his basketball background.  His father, Rich Grawer, is a decorated Hall of Fame Coach in the state of Missouri. Rich has the 2nd most career wins as the Head Coach at St. Louis University and is still recognized as one of the best basketball minds that has coached at both the high school and collegiate levels.  Brian was a 2x All-Big XII Honorable Mention awarded player from the University of Missouri-Columbia, where he was the starting point guard from 1997-2001. Standing only 5'10”, Brian found ways to be effective and impactful as a “little guy” in a “tall man's game”, through his hard work and mindful approach to the game, his teammates, and his coaches. He ended his career at Mizzou in the top 10 in multiple categories (Steals, 3-pointers made, 3pt %, and Ft %). He held the single-season FT % record (90.5%) for the last 24 years until that record was surpassed in the 2023-24 season at Mizzou.  One of his former coaches, Quin Synder, called Brian, “One of the best leaders he has ever seen.”  After he finished his playing career, Brian spent 3 years as an assistant coach at the college level. He then took his career to the pharmaceutical/Radiopharmaceutical sales path.  Brian is currently the Head of Cardiology Sales at Lantheus, which is a leading radiopharmaceutical-focused company with proven expertise in developing, manufacturing, and commercializing pioneering diagnostic and therapeutic products and artificial intelligence (AI) solutions.  In his 20+ year career in this industry, he has been in numerous different sales roles, both as an individual contributor and as a leader of a team.  Brian has been married to his wife, Angela, for 21 years.  They have two children, Addison (18) and Trent (13).   What You'll Learn in This Episode How preparation, purpose, and passion are the foundation of success The role of coachability in personal and professional growth Insights into transitioning from sports to business leadership Strategies for fostering loyalty and authenticity in teams The importance of self-reflection and vulnerability in leadership How to push yourself and your team out of your comfort zones for growth The parallels between leading on the court and in the boardroom Resources & Links Brian Grawer LinkedIn: https://www.linkedin.com/in/brian-grawer/ Website: www.Lantheus.com Twitter/X: https://x.com/bgrawer?lang=en   Ed Molitor LinkedIn: https://www.linkedin.com/in/themolitorgroup/ Website: https://www.themolitorgroup.com/   Timestamps [00:00:01] Introduction to trust in sales [00:05:12] Lessons learned from a Hall of Fame coaching father [00:12:34] Preparation, purpose, and passion in leadership [00:18:45] The power of coachability and self-reflection [00:25:29] Transitioning from basketball to business [00:30:18] Authentic leadership: Balancing vulnerability and accountability [00:38:45] Building a winning team culture [00:44:10] Advice for emerging leaders [00:50:05] Brian's most memorable basketball and leadership moments    

Molecule to Market: Inside the outsourcing space
Biopharma Insights: Live from J.P. Morgan

Molecule to Market: Inside the outsourcing space

Play Episode Listen Later Jan 24, 2025 39:44


In this episode of Molecule to Market, you'll go inside the outsourcing space of the global drug development sector with Dean McAlister, Executive Vice President at Inizio Biotech. Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Dean, covering: The evolving dynamics within the life sciences sector and how they are shaping outsourcing strategies Key insights and trends from J.P. Morgan week, including challenges and opportunities for CROs and CDMOs The Impact of cautious optimism on Business Development teams and commercial strategy in the current market Climate Why 2025 may be a year of incremental growth and how contract service providers can position themselves for success amidst swirling market headwinds The importance of strategic customer engagement and brand positioning for smaller, specialized players to gain an edge over global CDMO giants Dean brings a wealth of experience from his leadership role at Inizio Biotech, where he focuses on driving growth, innovation, and operational excellence. Prior to joining Inizio, he held executive leadership roles at AstraZeneca in US Commercial Sales and Market Access, leading teams of up to 1,100 people and overseeing high-impact strategies in a highly competitive environment.   Please subscribe, tell your industry colleagues and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We'd also appreciate a positive rating!   Molecule to Market is also sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

The Top Line
Recapping the 2025 J.P. Morgan Healthcare Conference

The Top Line

Play Episode Listen Later Jan 24, 2025 20:47


This year’s edition of the annual J.P. Morgan Healthcare Conference has come to a close, with attendees enjoying sunny skies and a heavy police presence throughout the San Francisco-set event. In this week’s episode of The Top Line, Fierce Pharma’s Zoey Becker and Angus Liu join Fierce Biotech’s Darren Incorvaia to break down the biggest news stories out of the conference. From Johnson & Johnson’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week just days before she left the White House, this year’s conference set the stage for what will surely be an eventful 2025. To learn more about the topics in this episode: ‘Own JP Morgan, don't let JP Morgan own you’: Biopharma—and Jill Biden—show up for JPM25 JPM25: Johnson & Johnson makes a splash, buying out Intra-Cellular Therapies for $14.6B JPM25: First Lady Jill Biden committed to improving women's health as White House tenure winds down JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care GSK-backed Ouro Medicines launches into T-cell engager space with $120M and a clinical-stage asset This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.See omnystudio.com/listener for privacy information.

Pharma and BioTech Daily
Pharma & Biotech Daily: J&J's Earnings, Chinese Licensing Deals, and Trump's Impact

Pharma and BioTech Daily

Play Episode Listen Later Jan 23, 2025 2:01


Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. During the latest Johnson & Johnson's Q4 earnings call, the company disclosed a total of $88.8 billion in sales for the full year. They also mentioned a shift in their acquisition strategy, moving towards smaller deals after the massive $14.6 billion purchase of Intra-Cellular. This change will see J&J focusing on single-digit billion buyouts in the future. Arrivent has joined the trend of Chinese licensing deals by potentially entering into a $1.2+ billion agreement with Lepu to advance an antibody-drug conjugate for gastrointestinal cancers. Meanwhile, Gilead is starting fresh after nearly five years into their $5 billion partnership with Galapagos, as they explore new opportunities with a spinoff company. President Trump's recent executive orders have sparked some concerns within the biopharma industry, despite most executives expressing a neutral stance towards his administration at the J.P. Morgan conference. The newsletter also covers topics such as FDA pausing Atara's programs, Chinese biotech Ascentage aiming for a $134 million IPO, and Johnson & Johnson's Spravato making advancements in the challenging depression space with monotherapy approval.Biopharma executives at J.P. Morgan maintained a neutral outlook towards the incoming Trump administration, but worries arose when Trump issued executive orders impacting the industry. Gilead's partnership with Galapagos is evolving after five years, leading to the creation of a new spinoff company. The rise of China's biopharma innovation may face obstacles due to Trump's trade policies. Other highlights from the newsletter include personal anecdotes from J.P. Morgan, Chinese biotech Ascentage gearing up for an IPO, SAGE taking legal action against Biogen, and investment trends for 2025 focusing on immunology and obesity. Notch Therapeutics announced layoffs, while companies like Akron Biotech, Visterra Inc., and Insmed Incorporated are currently hiring for various positions in the biopharma industry.

Unusual Whales
Episode 51: JPM Health Conference, Biotech, and Biopharma sponsored by BioPharmCatalyst

Unusual Whales

Play Episode Listen Later Jan 22, 2025 71:48


Episode 51: JPM Health Conference, Biotech, and Biopharma sponsored by BioPharmCatalystThis episode of the Unusual Whales Pod, sponsored and joined by BioPharmCatalyst, was recorded Live on January 21, 2025. Our host is joined by doctors and BioTech investors to discuss the 43rd JPM Health Conference. Covering a wide array of topics from expiring patents, to industry hopes and concerns with the incoming administration, BioPharmCatalyst walks us through what they're watching here at the top of 2025.Panel:BioPharmCatalyst https://twitter.com/BPharmCatalystChristian Marulanda https://x.com/crismarulandacDr. Jason Fung https://x.com/drjasonfungChristian Angermayer https://twitter.com/C_AngermayerHosted by: Nicholas FNS: https://twitter.com/NicholasFNSUnusual Whales: https://twitter.com/unusual_whalesThis Pod is not financial advice. Unusual Whales Inc. is not registered as a securities broker-dealer or an investment adviser with the U.S. Securities and Exchange Commission, the Financial Industry Regulatory Authority (“FINRA”) or any state securities regulatory authority. The stock market is risky, and any trade or investment is expected to have some, or total, loss. Please do research before any trade. Do not use this information for financial decisions or for investing. You should consult your legal or tax professional regarding your specific situation.Unusual Social Media:Discord: https://discord.com/invite/unusualwhalesFacebook: https://www.facebook.com/unusualwhalesInstagram: https://www.instagram.com/unusualwhales/Reddit: https://old.reddit.com/r/unusual_whales/TikTok: https://www.tiktok.com/@unusual_whalesTwitter: https://twitter.com/unusual_whalesTwitch: https://www.twitch.tv/unusualwhalesYouTube: https://www.youtube.com/unusualwhales/Merch: https://unusual-whales.creator-spring.com/

Biotalk
Biotalk Episode 23: 2024 Year-In-Review Report: Global Trends in Biopharma Transactions

Biotalk

Play Episode Listen Later Jan 21, 2025 13:46


During this episode of Biotalk, Geoff Meyerson, CEO of Locust Walk, unpacks our 2024 Year-In-Review Report: Global Trends in Biopharma Transactions Report. Geoff dives into the insights from the comprehensive report and offers a forward-looking perspective on what 2025 may bring for the biotech industry. Key topics include: Capital Markets Performance: The XBI ended flat, down 0.2%, underperforming the S&P 500's 24% gain. However, 2024 saw a 156% increase in capital raised compared to 2022, with IPO and follow-on financings improving in Q4. Venture Financing Trends: Q4 venture financing remained stable at ~$4B across 43 deals, with Series A and B rounds leading. Mega-rounds grew, including Kailera's $400M Series A and Metsera's $215M Series B. Strategic Transactions: Licensing deal value surged 135% in Q4, driven by early-stage deals, while M&A activity slowed, with no deals exceeding $5B. Regional Highlights: Europe and Asia saw a rise in venture and licensing activity, with Asia's cross-border deals and NewCo formations becoming key trends. This will be discussed further in a separate podcast. Market Outlook for 2025: With a new FTC chair, M&A and licensing deals are expected to rise in 2025. IPO markets will improve with gradually reduced interest rates, though risk aversion remains with private mega-rounds persisting to reduce financing risk. Geoff offers advice for navigating the current market and highlights Asia's growing role in global biotech. Stay tuned for our upcoming podcast on Asian markets.Listen now to gain insights into the evolving biopharma landscape, explore our report, and we welcome the opportunity to discuss its contents with you. Subscribe or follow Biotalk on Apple Podcasts | Spotify.   

The Top Line
Fierce's forecasts for the next year in biopharma

The Top Line

Play Episode Listen Later Jan 17, 2025 25:10


Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in layoffs, drug shortages, clinical trials and more play out in 2025. Meanwhile, a second Trump term and a spree of related health agency nominations raise serious questions about how health policy could shift over the next 12 months and beyond. In this week’s episode of “The Top Line,” we explore the trends that defined the industry in 2024 and tackle predictions about how 2025 could shake out for biopharmas big and small. Fierce Pharma’s Fraiser Kansteiner and Fierce Biotech’s Gabrielle Masson discuss 2024’s layoff count, the state of GLP-1 supplies, the future of clinical trial research, potential policy shakeups and more. To learn more about the topics in this episode: Analysts predict M&A, IPO uptick in 2025 but don't expect 'floodgates to suddenly open' Big Pharma layoff rounds jump 281% in '24, but overall industry rates similar to '23 2025 forecast: After Novo, Lilly expansion sprees, 'positive signals' emerge around future supply of GLP-1 drugs From AI and layoffs to supply chains and political unknowns, Deloitte outlines key areas for biopharma to watch in 2025 See omnystudio.com/listener for privacy information.

BioCentury This Week
Ep. 272 - JPM Deal Buzz & Rep. Auchincloss' Take on Biopharma

BioCentury This Week

Play Episode Listen Later Jan 13, 2025 27:29


J&J's $14.6 billion takeout of neurology play Intra-cellular Therapies headlined a buzzy start to the J.P. Morgan Healthcare Conference, where a flurry of deal announcements recalled the conference's pre-pandemic days. On the latest BioCentury This Week podcast, BioCentury's editors discuss the takeout of Intra-cellular, the third 11-digit neuro M&A in the past 13 months, as well as M&A involving Idrx and GSK, and Scorpion Therapeutics and Eli Lilly. Turning to Washington, the team explores what's behind BIO CEO John Crowley's visit to Mar-a-Lago to meet with President-elect Donald Trump, impending changes at FDA under Trump 2.0 and key takeaways from Rep. Jake Auchincloss appearance on BCTW's sister podcast, The BioCentury Show. The team also breaks down the key trends in the past year in FDA approvals. This episode of BioCentury This Week was sponsored by ICON Biotech.View full story: https://www.biocentury.com/article/65469400:01 - Sponsor Message: ICON Biotech02:38 - JPM Deal Buzz11:20 - Washington Update16:08 - Rep. Auchincloss' Take on Biopharma 21:01 - FDA Regulatory DecisionsTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

BioCentury This Week
Bonus Content - Trends in Global Biopharma Deals: Lazard's Kingston and Raine

BioCentury This Week

Play Episode Listen Later Dec 23, 2024 34:54


With most of the highly attractive late-stage assets already scooped up, pharmas are turning their sights to Phase II companies, and lining up their case to make an attractive offer and move fast. About 40% of the M&A deals in 2023-24 were completed in less than six weeks, from approach to announcement, according to Lazard's data. Michael Kingston and Dale Raine, global co-heads of biopharma at Lazard, joined The BioCentury Show this week to discuss the M&A outlook amid the still-precarious biotech financing landscape.The BioCentury Show, featuring BioCentury one-on-one with an industry KOL, is available on Apple, Spotify and wherever you listen to your favorite podcasts and in video podcast format on BioCentury's YouTube channel.View full story: https://www.biocentury.com/article/65385800:00 - Introduction03:01 - Capital Markets Outlook06:01 - M&A15:19 - Breaking Down Deals24:29 - AsiaTo submit a question to BioCentury's editors, email the BioCentury This Week team at podcasts@biocentury.com.Reach us by sending a text

Becker’s Healthcare Podcast
Navigating Biopharma's Future: Spencer Stuart Experts Discuss Industry Trends & Leadership Implications for 2025

Becker’s Healthcare Podcast

Play Episode Listen Later Dec 19, 2024 21:24


Niren Thanky and Lynn LaPierre, consultants from Spencer Stuart, join Becker's Healthcare to discuss the biopharma and life sciences industry trends they are watching for in 2025. They delve into the impacts of AI, GLP-1 drugs, private equity investment, and more, exploring their implications for leadership and the broader industry.This episode is sponsored by Spencer Stuart.